Live-attenuated Yersinia pestis vaccines

被引：2
|
作者：
Wang, Xiaoyi [1 ]
Zhang, Xuecan [1 ]
Zhou, Dongsheng [1 ]
Yang, Ruifu [1 ]
机构：
[1] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China
来源：
EXPERT REVIEW OF VACCINES | 2013年 / 12卷 / 06期
关键词：
live-attenuated vaccines; plague; Yersinia pestis; PNEUMONIC PLAGUE; BUBONIC PLAGUE; FUSION PROTEIN; PLASMINOGEN-ACTIVATOR; TRANSFERABLE PLASMID; PROTECTIVE IMMUNITY; PASTEURELLA-PESTIS; TRANS-TRANSLATION; RECEPTOR PROTEIN; SUBUNIT VACCINE;
D O I：
10.1586/ERV.13.42
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Plague caused by Yersinia pestis is one of the most dangerous infectious diseases. There is no ideal plague vaccine available for human use, but a number of licensed killed whole-cell and live-attenuated vaccines have been available in the past. Currently, there are a number of vaccines under development, including live-attenuated, DNA and subunit vaccines, among others. This review deals with the development of live-attenuated plague vaccines. Traditionally, live-attenuated plague vaccines have been developed by multiple passages of fully virulent Y. pestis, but they have not gained general acceptance due to safety concerns. Recent attempts to construct attenuated Y. pestis strains with specifically defined mutations have opened the door for developing new candidates for live-attenuated plague vaccines, with a proper balance between safety and protective efficacy.
引用
收藏
页码：677 / 686
页数：10
相关论文
共 50 条
  • [21] General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines
    Iwasaki, Masaharu
    Ngo, Nhi
    Cubitt, Beatrice
    Teijaro, John R.
    de la Torre, Juan C.
    JOURNAL OF VIROLOGY, 2015, 89 (23) : 12166 - 12177
  • [22] DNA-launched live-attenuated vaccines for biodefense applications
    Pushko, Peter
    Lukashevich, Igor S.
    Weaver, Scott C.
    Tretyakova, Irina
    EXPERT REVIEW OF VACCINES, 2016, 15 (09) : 1223 - 1234
  • [23] Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines
    He, Qing
    Martinez-Sobrido, Luis
    Eko, Francis O.
    Palese, Peter
    Garcia-Sastre, Adolfo
    Lyn, Deborah
    Okenu, Daniel
    Bandea, Claudiu
    Ananaba, Godwin A.
    Black, Carolyn M.
    Igietseme, Joseph U.
    IMMUNOLOGY, 2007, 122 (01) : 28 - 37
  • [24] Thoughts on the research of African swine fever live-attenuated vaccines
    Chu, Xuefei
    Ge, Shengqiang
    Zuo, Yuanyuan
    Cui, Jin
    Sha, Zhou
    Han, Naijun
    Wu, Bingrong
    Ni, Bo
    Zhang, Hui
    Lv, Yan
    Wang, Zhiliang
    Xiao, Yihong
    VACCINE, 2024, 42 (25)
  • [25] Reverse genetics approaches for the development of mammarenavirus live-attenuated vaccines
    Ye, Chengjin
    de la Torre, Juan C.
    Martinez-Sobrido, Luis
    CURRENT OPINION IN VIROLOGY, 2020, 44 : 66 - 72
  • [26] Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus
    Polack, Fernando P.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (09): : 1335 - 1337
  • [27] Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
    Hou, Jue
    Ye, Weijian
    Chen, Jianzhu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellins
    Rui, Haopeng
    Ritchie, Jennifer M.
    Bronson, Roderick T.
    Mekalanos, John J.
    Zhang, Yuanxing
    Waldor, Matthew K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) : 4359 - 4364
  • [29] Yersinia pestis (plague) vaccines
    Titball, RW
    Williamson, ED
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (06) : 965 - 973
  • [30] Using recombinant DNA technology for the development of live-attenuated dengue vaccines
    Lee, Hsiang-Chi
    Butler, Michael
    Wu, Suh-Chin
    ENZYME AND MICROBIAL TECHNOLOGY, 2012, 51 (02) : 67 - 72
12345